DOI: 10.36347/sjams.2017.v05i04.086

Pages: 1679-1683

Diabetes mellitus type 2 (DM) is a long term metabolic disorder that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Metformin is first line drug for diabetes mellitus due to its excellent safety and toleralability. Teneligliptin is newly approved drug for DM and having minimal side effects. Teneligliptin can be used either as monotherapy or add on therapy to metformin. Aim of the present study was to evaluate the effects of metformin and teneligliptin on HbA1c, fasting and postprandial blood glucose level at 12th, 24th week and to observe any side effect of drugs. This is case control study conducted at Department of General Medicine of a tertiary care centre. 100 adult patients (age >18 years) of type 2 DM were evaluated for possible inclusion in this study. All patients were randomly allotted into two groups. 50 patients were started with teneligliptin 20 mg/day along with metformin 1000 mg/day. 50 patients were started with placebo while continuing with metformin 1000 mg daily. Various parameters were measured at baseline, 12th week and 24th weeks. Total number of patients, mean age of patients and gender distribution were almost similar in both groups. Both group subjects had high FBS, PPBS and HbA1c at the start of study. After 24 weeks of treatment with teneligliptin and metformin, subjects had significant decrease in FBS, PPBS and HbA1c. There was no significant change in BMI, blood pressure and lipid parameters in both groups after study. All patients tolerated drugs well without any side effects. This study showed that teneligliptin can be an effective alternative to other drugs for add on therapy to the patients who are inadequately controlled with metformin alone.